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ABSTRACT

Chaney, Joseph Rashon. Ph.D., Purdue University, May 2015. Biochemical Investigation
of the Ubiquitin Carboxyl-Terminal Hydrolase Family Major Professor: Chittaranjan
Das.
The proteasome is the machinery in eukaryotic cells that degrades protein and
recycles the amino acids. Protein degradation is a highly regulated process which starts
by the attachment of chains of ubiquitin, which serves as a tag that marks a protein for
degradation. This function involves the work of several proteins at the proteasome that
work either as ubiquitin chaperones, ubiquitin binders or cleave ubiquitin from the
protein that is to be degraded. As this is a highly regulated process, various irregularities
can have deleterious effects including the onset of disease, including cardiovascular,
cancer, and neurological.
The focus of this dissertation is to study how residues located within and outside
the active site of Ubiquitin Carboxyl Terminal Hydrolase (UCH) deubiquinating enzymes
(DUBS) help regulate these enzymes interaction with the ubiquitin. I will provide
evidence that the putative oxyanion glutamine does function contribute to stabilization of
the oxyanion intermediate. Secondly, I will show that evidence that glutamine may also
serve another function within the active site by providing a CHO hydrogen bond that was
previously thought not to exist within the active sites of cysteine proteases. Lastly, I will
show that a conserved tryptophan in UCH37 has an effect on its catalytic viability.
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CHAPTER 1: INTRODUCTION

1.1

Ubiquitin-Proteasome System

The proteasome is the machinery in eukaryotic cells that degrades protein and
recycles the amino acids. Protein degradation is a highly regulated process. Ubiquitin is
attached to proteins marked for degradation. Ubiquitin however is not degraded by the
proteasome. Instead, the ubiquitin chain is cleaved by an enzyme at the proteasome cap
called deubiquitinating enzymes or DUBS. Proteins are tightly regulated in the cell by
the ubiquitin proteasome system. Ubiquitination is the covalent attachment of the 76
amino acid containing eukaryotic polypeptide ubiquitin and is an important reversible
post-translational modification of proteins in the cell. It helps regulates a wide variety of
biological process, such as cell cycle control, transcription, and protein quality control [35]. Ubiquitin is attached through an isopeptide bond between the C-terminal carboxyterminal group of ubiquitin and the Ɛ-amino group of a lysine side chain[1]. This
reaction is catalyzed by the sequential action of three enzymatic systems termed E1, E2,
and E3 [4]. Ubiquitin is first activated by E1 in an ATP-dependent reaction that results in
its installation on the E1 enzyme through a thioester bond between the c-terminal
carboxylic acid of ubiquitin and the catalytic cysteine of E1. The activated ubiquitin is
then transferred to the E2 enzymes catalytic cysteine residue. The E3 enzyme serves the
function of a protein ligase. E3 links ubiquitin to the acceptor protein’s lysine residue.
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Once this isopeptide bond is formed, more ubiquitins are linked to form a polyubiquitin
chain. There are estimated to be more than 600 E3 proteins found in the human genome
[5]. E3 are responsible for the type of polyubiquitin chain tagged to the proteins. The
type polyubiquitin linkages are identified by the lysine on ubiquitin and the carboxy
terminus of the next ubiquitin where the bond is formed. The linkages that have been
identified are K6, K11, K27, K29, K33, K48, and K63. Of these only the roles of K11,
K48, and K63 have been determined[6-10]. K11 and K48 both have been found to be the
primary linkage to confer proteasome degradation. While K63 linked substrates are
responsible for non-degradative functions such as cellular signaling, intracellular
trafficking, and ribosomal biogenesis [8-12]. The process is ultimately regulated by
deubiquinating enzymes (DUBs), which catalytic activities oppose that of the E3
enzymes by editing the polyubiquitin chain or cleaving the ubiquitin directly from the
substrate, creating more fee ubiquitin [12]. There are five classes of over 90 DUBs in the
human genome: the cysteine protease comprising the ubiquitin c-terminal hydrolases
(UCHs) family, the ubiquitin specific proteases (USPs) family, the ovarian tumor
proteases (OTU) family, the Machado-Josephin Domain protease (MJDs) family and the
last family, the JAB1/MPN/MOV34 (JAMM) protease family, are metalloproteases [1315].

1.2

Ubiquitin C-Terminal Hydrolases

Of the five DUB families, the ubiquitin c-terminal hydrolase family is unique
because there active sites contain a cross-over loop that restricts the substrate access .
There are four members of the UCH family; UCHL1, UCHL3, UCHL5 (UCH37), and
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BAP1 . It is the first DUB family to be identified however the substrate preference for
each enzyme has not yet been determined [18]. Each family member is composed of a
UCH domain with UCH37 and BAP1 having extensions at their c-terminus [1-3].
Ubiquitination is the covalent attachment of the 76 amino acid containing eukaryotic
polypeptide ubiquitin and is an important reversible post-translational modification of
proteins in the cell. It helps regulates a wide variety of biological process, such as cell
cycle control, transcription, and protein quality control [3-5]. Ubiquitin is attached
through an isopeptide bond between the C-terminal carboxy-terminal group of ubiquitin
and the Ɛ-amino group of a lysine side chain[1]. This reaction is catalyzed by the
sequential action of three enzymatic systems termed E1, E2, and E3 [13, 19]. Ubiquitin
is first activated by E1 in an ATP-dependent reaction that results in its installation on the
E1 enzyme through a thioester bond between the c-terminal carboxylic acid of ubiquitin
and the catalytic cysteine of E1. The activated ubiquitin is then transferred to the E2
enzymes catalytic cysteine residue. The E3 enzyme serves the function of a protein
ligase. E3 links ubiquitin to the acceptor protein’s lysine residue. Once this isopeptide
bond is formed, more ubiquitins are linked to form a polyubiquitin chain. The process is
ultimately regulated by deubiquinating enzymes, which catalytic activities oppose that of
E3 enzymes.

1.2.1

UCHL3

UCHL3 was one of the first structurally characterized in the UCH family and
also the smallest at just 8.6 kDa [15, 21]. The primary responsibility of UCHL3 has yet to
be determined. It is understood from structure that it has a crossover loop presumably for
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conferring substrate specificity [13, 20]. The loop is found to be disordered in the human
enzyme but takes an ordered conformation when bound to ubiquitin [15, 22]. UCHL3
shows hydrolase activity to linearly fused ubiquitin to small peptides [22]. It has been
found to be upregulated in uterine cervical neoplasms and to be a novel regulator in
prostate cancer cell lines [22, 23].

1.2.2

UCHL1

UCHL1 is a (223 amino acid), 24 kDa protein that belongs the UCH family of
DUBs. It is selectively expressed in the brain comprising 1-2% of all brain protein.
Mutations in UCHL1 have been linked to neurodegenerative diseases. UCHL1 has been
identified in lewy bodies in Parkinson’s disease [25]. UCHL1 is not expressed in normal
lung tissue. This gives UCHL1 implications in lung cancer tumor regulation and
metastasis[10]. UCHL1 monomer is composed of two lobes, a right and left. The right
lobe of L1 consisting of five αα helixes [10]. The left lobe of L1 consists of two αα
helices and six β strands. Between the lobes is a cleft that contains the catalytic residues.
The active site is composed of three secondary structural elements; αa helix, a ββ sheet,
and a loop. The helix contains the catalytic cysteine (Cys90). The β sheet contains the
catalytic histidine (His 161). The loop contains the catalytic aspartic acid (Asp 176) [26].
These three residues make up UCHL1 catalytic triad and are responsible for UCHL1’s
ability to cleave the isopeptide bond linked substrates from ubiquitin.
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1.2.3

UCHL5

UCHL5 (UCH37) is a 329 amino acid DUB of the UCH family. Its specific
function is for ubiquitin chain editing, presumably at the distal end, at the 19S
proteasome [27]. It has been found to dock to the 19S regulatory particle through the
interactions with the subunit Rpn13. UCHL5 and RPN13 share a similar construct in
their c-terminal region called a KEKE motif. The KEKE motif is a series of repetitive
lysine and glutamate residues. This motif is believed to be responsible for this
interaction. UCHL5’s activity toward poly-ubiquitin chains is mediated by its association
with RPN13, which provides an additional ubiquitin binding site for the poly-ubiquitin
chain. RPN13 is linked to the proteasome through an association with RPN2[28].

1.2.4

BAP1

BRCA1 associated protein 1 (BAP1) is the largest member of the UCH family. In
addition to the N-terminal UCH domain, it contains several interacting domains along
with a nuclear localization site (NLS) [28]. BAP1 interactes with the RING finger
domain of BRCA1 [29]. Sequence analysis identified the amino-terminal segment of
BAP1 as a ubiquitin hydrolase, which was confirmed through activity measurements
against a

Ub-OEt substrate mimic[30]. BAP1 is the last member of the UCH family

that has not had its structure determined. Further characterization of the enzyme revealed
that BAP1 contained two nuclear localization sites and that BAP1 co-immunprecipitated
with a splicing variant of BRCA1. This led to the understanding that the ubiquitin
degradation pathway could play a role in the regulation of BRCA1. Because the sequence
of BAP1 that interacts with BARD1 overlaps with the UCH domain (residues 182-365),
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it is still unclear if the deubiquitinating activity of BAP1 has any link to its role is breast
cancer[31].
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CHAPTER 2: CONTRIBUTION OF PUTATIVE OXYANION HOLE RESIDUE TO
CATALYSIS IN UCHL1, UCHL3 AND UCHL5

(Previously published as Boudreaux D, Chaney J, Maiti TK, Das C. Contribution of active site
glutamine to rate enhancement in ubiquitin C-terminal hydrolases. FEBS J. 2012.)

2.1 Abstract
Ubiquitin carboxy terminal hydrolases (UCHs) catalyze the hydrolytic removal of
ubiquitin from ubiquitinated proteins. These deubiquinating enzymes are cysteine
proteases featuring a classical cysteine-histidine-aspartate catalytic triad, also a highly
conserved glutamine thought to be a part of the oxyanion hole. However, the contribution
of this side chain to the catalysis by UCH enzymes is not known.
In this study, we demonstrate through mutational analysis that the putative
oxyanion-stabilizing side chain contributes to rate enhancement in UCHL1, UCHL3 and
UCHL5. Mutation of the glutamine to alanine in these enzymes reduces the catalytic
efficiency, mainly due to a 16 to 30-fold reduction in kcat (2 kcal/mol).

2.2 Introduction
Ubiquitin carboxy-terminal hydrolases (UCHs) belong to a larger group of
enzymes collectively called deubiquitinases (DUBs), which catalyze the hydrolysis of the
peptide or isopeptide bond through which ubiquitin is attached to other proteins or other
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ubiquitin moieties in polyubiquitin chains [12, 35, 36]. The UCH family members are
cysteine proteases featuring a classical cysteine-histidine-aspartate catalytic triad [12, 15,
16, 22]. The active site of these enzymes also features a highly conserved glutamine
residue (Fig. 2.1) believed to be a part of the so-called oxyanion hole, an arrangement of
spatially proximal peptide dipoles aligned in a way that creates a positively charged
pocket facing the thiol group of the catalytic cysteine. It is also possible that, by virtue of
being located at the N-terminus of a helix, the electropositive character of this pocket is
enhanced by the helix macro dipole effect [6]. In cysteine proteases, nucleophilic attack
of the carbonyl group on the scissile peptide bond proceeds through a tetrahedral
transition state bearing a

negative charge on the oxygen atom of the carbonyl group.

This negative charge is stabilized by electrostatic and hydrogen-bonding interactions with
the oxyanion hole, which is proposed to be one of the factors leading to the lowering of
activation energy for the hydrolysis reaction [6].
The relative orientation of the carbonyl oxygen of the scissile peptide group with
respect to the oxyanion-stabilizing groups, as in the tetrahedral transition state, may be
approximately visualized in the crystal structure of the yeast ubiquitin hydrolase Yuh1
bound covalently to the suicide substrate ubiquitin aldehyde (Ubal) (Fig. 2) [6]. Attack of
the catalytic thiol on Ubal results in the formation of the thiohemiacteal product, which
mimics the oxyanion-bearing tetrahedral transition state (Fig. 2). As seen in Figure 2, the
hydroxyl oxygen of the thiohemiacetal moiety is within a relatively short distance from
the backbone NH groups of the catalytic Cys90, Ala89, Asn88 and the side chain NH2
group of Gln84, the putative oxyanion-stabilizing side chain. It has been proposed that in
a general cysteine protease, the negatively charged oxygen in the tetrahedral transition
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state would occupy nearly the same position as the thiohemiacteal hydroxyl oxygen seen
in the Yuh1-Ubal structure and would be coordinated through electrostatic and hydrogenbonding interactions by the groups lining the oxyanion hole [7].
Papain, an extensively studied cysteine protease, revealed that Gln19, the
oxyanion side chain in the protein, plays a role in the catalytic mechanism of the enzyme
contributing to rate enhancement [7]. Mutation of this side chain to alanine reduces the
catalytic efficiency approximately 60-fold, mostly affecting kcat (20-fold lower) with a
relatively smaller change in KM (3-fold higher) [8]. Ignoring the relatively small change
in KM, the 20-fold change in kcat was attributed to a loss of the contribution of the
glutamine side chain to oxyanion stabilization. The catalytic Cys-His-Asp triad of
structurally characterized UCH enzymes, such as UCHL1, UCHL3 and UCHL5, adopts a
similar geometric relationship as found in the Cys-His-Asn triad of papain and the triads
of other papain-like cysteine proteases. Additionally, the active-site glutamine in UCH
enzymes is located in an identical location as the as Gln19 in papain. However, the role
played by this side chain in the catalysis by UCH enzymes has not been studied thus far.
Considering the importance of the UCH group of proteases in diseases such as
Parkinson’s disease and cancer, understanding the role of active site residues in catalysis
is important for our overall understanding of the mechanism of these enzymes[9]. We
sought to determine the contribution to rate enhancement by the putative oxyanion
glutamine.
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2.3 Materials and Methods
Ubiquitin 7-amido-4-methylcoumarin (Ub-AMC) used for hydrolysis assays was
acquired from Boston Biochem (Boston, MA). The glutathione affinity column (GSTPrep
FF 16/10), gel filtration column (HiLoad 16/60 Superdex 75) and PreScission protease
were purchased from GE Biosciences (USA). All fluorescence assays were performed on
a TECAN Genios microplate spectrofluorometer. Buffer and salt components were
purchased from either Sigma-Aldrich (St. Louis, MO) or RPI Corp (Mount Prospect, IL).

2.3.1

Mutagenesis, Protein Expression and Purification

UCHL1, UHCL3, UCHL5N240 were cloned into the pGEX-6P-1 vector using
standard protocols and subsequently used to mutate the active-site glutamine to alanine
through PCR reactions using the Quickchange II (Agilent; Santa Clara, CA) site-directed
mutagenesis kit. All plasmids were transformed into Rosetta2 E. coli cells and grown to
an ODλ600nm= 0.6 in LB media supplemented with 100 μg/mL ampicillin then induced
with 0.5 mM isopropyl β-thiogalactoside and grown overnight at 18°C. Cells were
harvested at 6,000 × g and resuspended in 1X PBS + 400 mM KCl (buffer A). Cells were
passed through a French press twice at 1,200 psi and the lysate cleared by centrifugation
at 30,000 × g for 1 hour. The supernatant was loaded onto a glutathione affinity column,
washed with 3 column volumes of buffer A and eluted with 250 mM Tris, 500 mM KCl,
10 mM reduced L-glutathione, pH 8.0. The eluted sample was dialyzed against 1X PBS,
400 mM KCl, 1 mM DTT to which PrecissionProtease was added to remove the
glutathione S-transferase (GST) tag, which was captured onto a glutathione-agarose
affinity column. The resulting GST-cleaved protein solution was passed through a
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Superdex S75 gel filtration column with 50 mM TRIS-HCl (pH 7.6), 150 mM NaCl and
1mM DTT. Fractions containing purified protein were pooled, concentrated then flash
frozen in liquid nitrogen and stored at -80 °C until use.

2.3.2

Analysis of Oxyanion Mutants

Each of the UCH enzymes was diluted in assay reaction buffer (50 mM Tris pH
7.6, 0.5 mM EDTA, 0.1% BSA, 5 mM DTT) so the final concentration in the reaction is
the following: UCHL1 (2 nM), UCHL1 Q84A (8 nM), UCHL3 (5 pM), UCHL3 Q89A
(175 pM), UCHL5N240 (500 pM), UCHL5N240 Q82A (3 nM), UCHL3 Q89E (12 pM),
UCHL3 Q89K (50 pM). Enzyme was added to a 96-well plate and incubated at 30°C for
5 min prior to addition of Ub-AMC diluted in assay reaction buffer to initiate the
reaction. Rates of Ub-AMC cleavage was monitored with an excitation λ = 380 nm and
an emission λ = 465 nm at 30°C. Initial reaction rates were calculated and plotted versus
Ub-AMC concentration in SigmaPlot and fitted to the Michaelis-Menten equation to
determine KM and kcat values.

2.4 Results

2.4.1 Alanine Mutants Show Modest Loss of Activity
In order to determine if the conserved glutamine residue found in the active site of
UCH enzymes (fig. 2.3) contributes to rate enhancement, hydrolysis assays using the
fluorogenic substrate Ub-AMC were conducted using identical conditions for each set of
enzyme and its glutamine to alanine mutant. These results show that the rate of
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hydrolysis leading to AMC release is significantly reduced in the mutants compared to
their wild-type enzymes seen in figure 2.3, suggest that this side chain plays some role in
the catalytic mechanism of the enzymes. Since glutamine is located in the solventaccessible active site of the enzymes, the mutation of this residue to alanine is not
expected to cause any significant perturbation in the active-site structure or gross changes
in the three-dimensional fold of the protein. In fact, the circular dichroism spectra of the
mutants produce a pattern that is nearly identical in shape and intensities to their
corresponding wild-type proteins confirming that the mutation has no observable
structural effect in these proteins [10-12].
The loss in catalytic activity observed upon mutation could be attributed to two
possible factors: an increase in the Michaelis constant KM, or a reduction in kcat, the rate
constant of the rate determining step in the hydrolysis reaction. In order to know which
parameters are affected by the mutation, we set out to analyze the Michaelis-Menten
kinetics of the mutants and the wild-type enzymes. Additional activity assays were
conducted with varying substrate concentration and plots of the initial velocities versus
substrate concentration are shown in figure 2.4 All enzymes with the exception of
UCHL5N240 Q82A were fit to the Michaelis-Menten equation (figure 2.4). Non-linear
regression analysis of the plots yielded the kinetic parameters kcat and KM for each UCH
variant and their values are provided in Table 2.1. The values of the kinetic parameters
obtained with wild-type enzymes are consistent with previously reported values . The
glutamine to alanine mutants showed a 30 and 18-fold decrease in kcat, for UCHL1 and
UCHL3, respectively, compared to their corresponding wild-type enzymes. However, KM
values were relatively unchanged due to the mutation, which is consistent with the
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hypothesis that the glutamine residue is involved in the catalytic mechanism of the
enzyme.
In the case of UCHL5N240 Q82A, kcat and KM could not be determined
individually because, even at concentrations of Ub-AMC as high as 12 M, the
Michaelis-Menten plot was still rising linearly with substrate concentration, not reaching
the plateau that is diagnostic of saturation. Substrate concentrations greater than 12 M
result in DMSO concentrations higher than 5%, which can diminish the enzyme’s
activity. Instead, the ratio kcat/KM was determined by dividing the slope of this linear plot
by the total enzyme concentration since it can be assumed that in this region of the
Michaelis-Menten plot, [Ub-AMC] << KM. Comparison of this value for the wild-type
and Q82A variant of UCHL5N240 shows a 16-fold reduction in catalytic efficiency,
which is comparable to the reductions seen with UCHL1 and UCHL3 suggesting that the
Gln82 residue is likely performing the same function as in the other UCH enzymes.
In order to determine the effect of these mutations on the stabilization of the transition
state, we sought to estimate the change in free energy of activation associated with the
mutation. The calculation was carried out using equation 2.1 and the kcat/KM values
mentioned above and reported in Table 2.1 [11]. The free energy change for the three
enzymes is approximately 2 kcal/mol, which is consistent with the value reported for the
same mutation in papain [11].

 (k /K )

G ≠ = -RT ln  cat M mutant 
 (k cat /K M ) wild-type 

Equation 2.1
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The active-site glutamine in UCH enzymes is involved in a C—H•••O hydrogen
bond with CH of the catalytic histidine

2.5 Discussion
The UCH subfamily of dubiquitinases are cysteine proteases with a catalytic triad
similar to that seen in the papain family. In each member of this family, like papain, there
is a conserved glutamine residue located in the active site of the enzymes believed to
stabilize the incipient negative charge on the carbonyl of the scissile bond during the
transition state of the hydrolysis reaction (Scheme 2.1). Indeed, mutation of the Gln19 in
papain to alanine resulted in a 60-fold decrease in catalytic efficiency due mainly to a
diminished catalytic rate (20-fold) and a small loss in substrate binding (3-fold). These
results support the claim that the conserved glutamine side chain contributes to the
stabilization of the oxyanion transition state. Given the similarity in certain active-site
residues between papain and members of the UCH family, we wondered if the glutamine
would perform a similar role in the UCH family. Our study sought to address the role of
the conserved glutamine in rate enhancement in three UCH enzymes.
Through site-directed mutagenesis, the active-site glutamine in three structurally
characterized members of the UCH family was replaced with alanine in order to assess
the contribution of this side chain to rate enhancement. Deubiquitination assays show
there is a significant loss of activity in mutant enzymes compared to their wild-type
counterparts. Comparison of the kinetic parameters shows a 16 to 30-fold loss (~2
kcal/mol) in the catalytic efficiency for the glutamine mutants, which is due mainly to a
decrease in the kcat parameter, as seen in UCHL1 and UCHL3 (for the mutant UCHL5,
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kcat and KM could not be separately determined). These results are in agreement with the
aforementioned results from papain, although the UCH enzymes did not exhibit the same
change in the KM value. The kinetic scheme for UCHL1 has been worked out by Case
and Stein using the same Ub-AMC substrate [10]. Their study shows that the rate of
acylation is rate-limiting for kcat, which means KM reduces to the dissociation constant
(Kd) of the Michaelis complex. The fact that we are not seeing any significant change in
KM suggests that Gln84 in UCHL1 does not contribute to the enzyme-ground statesubstrate complex. Therefore, in UCHL1, according to our studies, the active site
glutamine does not make any appreciable contact with the substrate in the Michaelis
complex; rather it helps to stabilize the transition state.
The kinetic scheme for UCHL3 remains to be worked out. However, kcat values of
UCHL3 catalyzed hydrolysis of ubiquitin ethylester and Ub-lysine are very similar to that
obtained with Ub-AMC as the substrate, suggesting that deacylation might be the ratelimiting step [13]. In such a case, KM is not the simple dissociation constant of the
Michaelis complex. Nevertheless, the fact that KM changes only slightly upon glutamine
to alanine mutation in UCHL3 is consistent with the inference that the glutamine does not
appreciably contribute to Michaelis complex.
As discussed before, we could not separately measure kcat and KM for
UCHL5N240 Q82A; rather, the ratio was measured, which is about 16-fold less than the
wild-type protein. It is possible that the ratio reflects a change mostly in kcat, like UCHL1
and UCHL3, due to the structural similarity between the proteins. However, it cannot be
ruled out that UCHL5N240 employs a different mechanism than UCHL1 and UCHL3. It
is possible that there was a much larger change in kcat that was compensated by an
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opposite change in KM. Alternatively, there was little or no change in kcat and the
observed effect was due mostly to a change in KM. The latter possibility seems rather
unreasonable since the glutamine is located in an almost identical position as in the other
enzymes and therefore its effect on stabilizing the Michaelis-Menten complex is expected
to be the same.
Our results indicate the mutation of glutamine to alanine results in a significant
decline in the catalytic rate, which supports the hypothesis that glutamine is functioning
to stabilize the transition state intermediate(s). However, one expects that the change
would be much greater than 30-fold as seen in our system if the mechanism were through
the stabilization of the oxyanion, which has been proposed to involve hydrogen bonding
between the NH2 group of the side chain of glutamine and the negatively charged oxygen
ion, given that such hydrogen bonds are particularly strong. For example, mutation of the
oxyanion-stabilizing residue Tyr16 to phenylalanine in ketosteroid isomerase results in a
20,000-fold (6.3 kcal/mol) reduction in kcat [9]. One explanation for the discrepancy
between the result of the mutation of the oxyanion-stabilizing side chain in ketosteroid
isomerase compared to our system is that, in the latter, the side chain of glutamine is not
solely responsible for stabilizing the oxyanion through hydrogen bonding; rather, it is
playing a role in contributing to the overall electropositive character of the oxyanion hole.
As shown in Figure 2.2, a number of αNH dipoles from surrounding backbone residues
can still support a significant degree of oxyanion stabilization even in the absence of the
glutamine side chain. Since main-chain atoms cannot be removed by traditional
mutagenesis methods, the individual contribution of each atom cannot be determined, nor
can we determine if the glutamine plays a more significant role than the individual
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backbone atoms. The alternative possibility that the transition-state stabilization by the
glutamine side chain is reflecting a somewhat weaker hydrogen bond owing to a longer
distance between the donor and the acceptor (discussed further in Chapter 4) cannot be
ruled out.
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Table 2.1: Kinetic Parameters for UCH Enzymes showing decrease in kcat/KM from wild
type to Ala mutants [1]
Enzyme

KM (nM)

kcat (s-1)

kcat/KM ×104 (M-1
s-1)

UCHL3

77.1 ± 8.2

18.60 ± 0.60

24140

ΔΔG‡
(kcal/mol)

1.89
UCHL3 Q89A

99.1 ±
13.5

UCHL1

47.0 ± 6.0

UCHL1 Q84A

56.1 ± 2.3

UCHL5N240

21493.2

UCHL5N240
Q82A

1.03 ± 0.05
0.0348 ±
1.25×10-3
0.0011 ±
1.50×10-4
33.67

1040
74.1
2.19
1.96
15.7
1.68

—

—

0.966
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CHAPTER 3: CONSERVED HYDROPHOBIC MUTATION IN
UCH ENZYMES HAS VARIED ROLE AS IT RELATES TO UBIQUITIN

3.1 Abstract
Ubiquitin carboxyl terminal hydrolase (UCH) enzymes release small peptide and
protein leaving groups from the C-terminus of ubiquitin. Although the interaction with
ubiquitin is fairly well understood in these enzymes, recognition of the isopeptide moiety
of the substrate at the active site has not been well characterized. The crystal structure of
TsUCH37 (T. spiralis) bound to the suicide substrate, UbVMe, reveals a conserved
tryptophan residue that may play a role in stabilizing the isopeptide linkage in the active
site. To study the contribution of this tryptophan residue, the equivalent residue in
human UCH37, W58, was mutated to alanine and phenylalanine. The phenylalanine
mutant retained most of its ubiquitin-AMC (Ub-AMC) hydrolysis activity as compared to
the wild type enzyme, but the alanine mutant was substantially impaired. The loss of
activity with the alanine mutant is not due to any alteration in the three-dimensional fold
of the enzyme. Considering the distance of this tryptophan residue from G76 of ubiquitin
(>5 Å), this observation suggests that W55 may be involved in binding to the AMC
portion of the Ub-AMC substrate, which may indicate that it makes contact with the
isopeptide moiety in ubiquitin-linked substrates. This has been further investigated using
UCHL3 as a model.
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3.2 Introduction
Uch37 is a member of the ubiquitin carboxyl terminal hydrolase family. It is the
only member of the family that has been found to be a resident of the proteasome. Uch37
binds to the 19s cap through an interaction at its C-terminus with the C-terminus of
Rpn13 [2]. It is believed that this interaction activates Uch37 for cleavage of
polyubiquitin chains by relieving the auto inhibition of the active site by helix 9, though
this has yet to be experimentally proven [3, 4]. However this interaction provides
additional ubiquitin binding sites that may contribute to the effectiveness of Uch37
cleaving polyubiquitin chains. Uch37 has not shown to be activated unless it is bound to
the 19S proteasome cap. At the proteasome Uch37 takes the role of chain as it process
polyubiquitin chains at the distal end. Ubiquitin carboxyl terminal hydrolase (UCH)
enzymes release small peptide and protein leaving groups from the C-terminus of
ubiquitin . Although the interaction with ubiquitin is fairly well understood in these
enzymes, recognition of the isopeptide moiety of the substrate at the active site has not
been well characterized. It was recently found that the tryptophan residue (Trp55) of
TsUCH37 which is near the active site was in a particular confirmation that suggested it
may interact with the isopeptide bond between ubiquitin and its linked substrates [5].
The crystal structure of TsUCH37 (T. spiralis) bound to the suicide substrate,
UbVMe, reveals a conserved tryptophan residue that may play a role in stabilizing the
isopeptide linkage in the active site [5]. Considering the distance of this tryptophan
residue from G76 of ubiquitin (>5 Å), this observation suggests that W55 may make
contact with the isopeptide moiety in ubiquitin-linked substrates and have a role in
ubiquitin binding or substrate release. We found this interaction to be very intriguing, as
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it made us wonder the significance of this individual residue. We hoped to identify if this
tryptophan assists with monoubiquitin binding or does it have an effect on the ability of
Uch37 to cleave ubiquitin bound substrates. It has been further suggested that the Trp55
residue may provide important contacts with the isopeptide link, properly positioning for
cleavage at the active site [5].

3.3 Materials and Methods
Mutagenesis primers were ordered from Sigma Aldrich for Uch37(1-240) W58A
and W58F. Using a Bioneer mutagenesis kit the mutagenesis was performed using
standard parameters on the PCR thermocycler. After PCR thermocylcling was compete
the resulting mixtures were treated with the DPN1 enzyme to remove methylated parental
DNA. The resulting mutagenesis reaction was transformed using Rosetta cells and plated
overnight in a 37˚C incubator. The resulting plate produced a number of colonies. The
mutant DNA was extracted using a mini-prep purification kit. The mutant DNA was
submitted for sequencing to the Purdue Genomics Facility. The sequence results
confirmed each mutation was successful (figure 3.2, 3.3, 3.4). The resulting DNA was
transformed into Rosetta Component Cells.

3.3.1

Mutagenesis, Protein Expression and Purification

A 75 mL starter culture of Lennox broth (LB) inoculated with 100

/

Ampicillin

and Escherichia coli cells containing the desired protein construct. This culture was
incubated at 37°C with vigorus shaking overnight. The next day 6 x 1L of LB media was
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inoculated with 100

/

Ampicilin and 8 mls of the starter culture. The 6L cultures

were grown to an optical density (O.D.λ=600nm) = 0.400 and then induced with 1.0 mM
isopropyl B-D-1-thiogalactopyranoside (IPTG). The cultures were then allowed to grow
overnight at 18°C.
Cells were harvested by centrifugation at 7000 x g for 10 minutes and
resuspended in 60 mL of 1 X PBS buffer (phosphate-buffered saline plus 400 mM KCl).
The cells were then lysed by French press at 1,000 psi after incubating for 30 minutes
with approximately 600 mg of Lysozyme. The pressed cells were then centrifuged at
1200 rpm (30,000 x g) to pellet the cell debris. The supernatant collected was then loaded
on to a GSTPrep FF 16/10 glutathione sepharose affinity column, equilibrated with the 1
X PBS solution, at a flow rate of 1ml/min. The column was then washed with the 60 ml
of 1 X PBS buffer plus 400 mM KCl to remove non-specific binding elements. The
desired protein was eluted with approximately 30 ml of elution buffer (250 mM
Tris•HCL, 500 mM KCl, 10 mM reduced glutathione, pH 8.0). About 500 units of
PreScission Protease, a 47 kDa protein that recognizes and cleaves GST region of the
protein between a Gln and Gly residues, was added to the eluted solution (citation needed
GE website). This results in free GST (26 kDa) and free protein containing plus GPLGS
peptide on the N-terminal. The solution was dialyzed overnight at 4°C in a 1 X PBS
buffer plus 400 mM KCl, to allow for sufficient cleavage of the GST tag. The solution
was then loaded on to the GSTPrep FF 16/10 glutathione sepharose affinity column
allowing the GST free protein to pass through the column while the cleaved GST stays
bound in a process called GST subtraction. Fractions were taken from each step of the
purification process and run on an SDS PAGE Gel for successful verification of the

36
isolated protein of interest. The protein was then concentrated by centrifugation to 4 ml,
filtered through a .25 micron syringe filter and loaded onto an S75 gel filtration column
on an Akta protein purification system (GE Healthcare Life) with a running buffer of 50
mM Tris-HCL 50 mM NaCl and 1 mM DTT (pH 7.4). The protein was collected in 2 ml
fractions. An SDS PAGE Gel was run on the collected fractions to quantify were the
protein eluted. The fractions containing the most concentrated eluted protein was then
pooled and concentrated to around 2 ml. A small sample of protein taken for
concentration measurement and the rest was aliquoted into 100 ml epindorf tubes, flash
frozen in liquid nitrogen, and stored in -80˚C Ultra Freezer.

3.3.2

Kinetic Analysis of Oxyanion Mutants

Each of the hUCH37 (hUch37N240 WT, hUch37N240 W58A and hUch37N240
W58F) and UCHL3 (UCHL3 and UCHL3 I58A) enzymes were diluted in assay reaction
buffer (50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% BSA, 5 mM DTT) so the final
concentration in the reaction is the following: Uch37N240 WT (1 nM), Uch37N240
W58A (1 nM), Uch37(N240)W58F (1 Nm), UCHL3 (50 pM), UCHL3 I58A (50 pM).
Enzymes were added to a 96-well plate and incubated at 30°C for 5 min prior to addition
of Ub-AMC diluted in assay reaction buffer to initiate the reaction. Rates of Ub-AMC
cleavage were monitored with an excitation λ = 380 nm and an emission λ = 465 nm at
30°C.
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3.3.3

Circular Dichroism

Each of the hUCH37 (hUch37N240 WT, hUch37N240 W58A and hUch37N240
W58F) were buffer exchanged into 1 X PBS buffer pH 7.4, to remove all traces of Tris
HCL which absorbs strongly at 210 nm. Each protein was diluted to the final following
concentrations: Uch37N240 WT (5 nM), Uch37N240 W58A (5 nM), Uch37N240 W58F
(5 nM). CD spectra were obtained using a wavelength scan on a JASCO J-810
spectrophotometer. Scans were conducted in the region of 260 to 190 nm. Scans were
corrected for blank and raw data converted to molar ellipticity.

3.3.4

Isothermal Titration Calorimetry

All solutions were dialyzed against 50 mM Tris-HCl 1mM TCEP. In the titration
of hUCH37N240 (WT) and ubiquitin, ubiquitin was diluted in buffer to 10 mM in
syringe. hUCH37N240 (WT) was at a diluted to a concentration of 200 uM in cell. In the
titration of UCH37-RPN13N268 complex and Ubiquitin, the complex was diluted to a
concentration of 100 uM in cell. Ubiquitin was diluted in buffer to 2 mM in syringe. In
the titration of hUCHL3 (WT) and ubiquitin and hUCHL3 I58A, ubiquitin was diluted in
buffer to 500 μM in syringe. Both hUCHL3 (WT) and hUCHL3 I58A were diluted to a
concentration of 59 μM for each titration. All ITC experiments were carried out by
titrating free ubiquitin in syringe into the cell containing the respective UCH enzyme.
Data was analyzed and fitted to a one-site binding model corresponding to a single site
binding free ubiquitin to the perspective UCH enzyme being tested. Binding isotherm
plots were produce from the integration of the heat of release vs. time for each ubiquitinenzyme pair.
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3.4 Results

3.4.1

hUCH37N240 W58A and hUCH37N240 W58F

The tryptophan (55) residue of TsUCH37 was observed to make contact with the
OMe group, in the structurally characterized, TsUCH37cat-UBVME which suggest an
important contact with the hydrocarbon area of the isopeptide bond of an actual ubiquitin
attached substrate [1]. We mutated this tryptophan (58) residue, conserved in all UCH37
homologs, in hUCH37 to alanine and phenylalanine to test whether this contact is
important for substrate binding or ubiquitin interaction with UCH37. The result was that
the UCH37 enzyme showed no difference in Ub-AMC release between the hUCH37(1240) (wild-type)

and the W58F mutant. This comes as no surprise because the

phenylalanine (F) mutation was a hydrophobic and structurally conservative mutation
from the tryptophan (W) of that position and no change was expected. However, the nonconservative mutation of W58A, gave a significant decrease in UCH37 ability to
hydrolyze the Ub-AMC in comparison to the truncated wild-type and W58F mutation as
revealed in figure 3.5. We attempted to quantify this change using Isothermal
Calorimetry measurements of the hUCH37N240 (WT) and hUCH37N240 W58A. ITC
of the hUCH37N240 showed a very weak interaction with ubiquitin because it was
outside of the KD of the ITC (KD < 1 mM) and is estimated to be near 10.5 mM. ITC of
the mutant hUCH37N240 W58A was not performed because the due to the WT protein
not showing measurable binding to ubiquitin. We decided instead to measure the KD of
UCH37-RPN13N268 complex. This is because previous literature indicates that UCH37
has an increased affinity to ubiquitin when in complex with Rpn13, a resident of the
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proteasome [5]. The ITC measurement of the complex also proved to be just outside of
the range of the instrument and is estimated to be a KD: 1.6 ± 0.7 mM. So ITC proved to
be not a conclusive way to determine whether the tryptophan mutation affects ubiquitin
binding to hUCH37.

3.4.2

UCHL3I28A

The tryptophan of the hUCH37 is conserved in and other homologs [5].
However sequence alignment of the UCH family as seen in figure 3.1 shows an
isoleucine present in a similar position in UCHL3. We decided to test whether mutation
to alanine would have the same effect as witnessed in hUCH37. Also UCHL3 provides
an excellent model substrate because of its high affinity to ubiquitin. However, we
observed that this mutation had almost no effect on UCHL3 ability to catalyze Ub-AMC
as seen in figure 3.11. Similarly, analysis of the ITC data (figure 3.12) indicates that
UCHL3 wild type protein and UCHL3I28A bind ubiquitin with dissociation constants
(KD) of 669 ± 60 nM and 456 ± 62 nM, respectively. We interpret from this that this
isoleucine has no significant impact in ubiquitin binding or AMC release.

3.5 Discussion
We sought to determine the contribution the role of the conserved tryptophan found near
the active site of hUCH37N240. Through site-directed mutagenesis, the tryptophan residue,

the equivalent residue in human UCH37, W58, was mutated to alanine and
phenylalanine. The phenylalanine mutant retained most of its ubiquitin-AMC (Ub-AMC)
hydrolysis activity as compared to the wild type enzyme, but the alanine mutant was
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substantially impaired. The loss of activity with the alanine mutant is not due to any
alteration in the three-dimensional fold of the enzyme. Considering the distance of this
tryptophan residue from G76 of ubiquitin (>5 Å), this observation suggests that W55 may
be involved in binding to the AMC portion of the Ub-AMC substrate, which may indicate
that it makes contact with the isopeptide moiety in ubiquitin-linked substrates. UCHL3,
another structurally characterized member of the UCH family and excellent model DUB,
was also studied by mutating the isoleucine, analogous to hUCH37 tryptophan, in order
to assess the contribution to the isopeptide link near the active site. UB-AMC
deubiquination assays show there is a significant loss of activity in the UCH37 W58A
mutant enzymes compared to its wild-type counterparts. However, no effect was
observed in the same assay with UCHL3 I58A and UCHL3 wild-type. ITC analysis
indicates that UCH37 does not tightly bind ubiquitin. We tested UCH37, UCH37 W58A,
and UCH37-RPN13N268 complex but not able to observe appreciable binding to monoubiquitin. We can reasonably determine that the tryptophan does have an appreciable impact on
hUCH37 ability to cleave ubiquitnated substrates based on the Ub-AMC experimental results. It
would be reasonable to assume that this interaction is with the isopeptide bond and substrate and
not with ubiquitin binding just based on distance (> 5 Å). What we also can determine is that this
interaction is not seen in UCHL3 and based on structural similarity we can also rule out this
effect in UCHL1. However, at this time we are not able to experimentally rule out its effect on
ubiquitin binding.
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CHAPTER 4: C—H•••O HYDROGEN BONDS IN CYSTEINE PROTEASES

4.1 Abstract
Cysteine proteases have been extensively studied for their importance in a wide
variety of biological processes such as apoptosis (Caspases), regulated proteolysis
(ubiquitin hydrolases), and calcium signaling (Calpains). The mechanism of these
proteolytic enzymes is relatively well known: it involves a catalytic diad of a cysteinehistidine pair, or a triad with additional help of either an aspartic acid or asparagine. An
analysis of structurally characterized cysteine proteases found in Merops Database
reveals the presence of a close contact between the catalytic (His)CƐ and, most often, the
O=Cδ of the putative oxyanion hole residue glutamine or a backbone carbonyl oxygen.
This contact follows the requirements of a C-H---O hydrogen bond as previously reported
for serine proteases (1). We speculate that this C-H---O interaction may play a role in the
catalysis by either altering the pKa of the general- base His and/or by keeping the
oxyanion-stabilizing side chain in a productive orientation. Upon further analysis, we
found that the oxyanion-stabilizing side chain, glutamine of ubiquitin carboxyl terminal
hydrolases are engaged in a C—H•••O hydrogen-bonding interaction with the catalytic
histidine, a feature that is common in most cysteine proteases, including papain,
belonging to families with the QCH(N/D) type of active-site configuration. It is possible
that removal of the glutamine side chain might have abolished this interaction, which
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typically accounts for 2 kcal/mol of stabilization, leading to an effect on catalysis
observed here. We investigated this further by making an additional mutation of the
glutamine to glutamic acid and lysine in UCHL3.

4.2
C—H•••O

Introduction

hydrogen bonds have generally been identified by Taylor and

Kenard[2] where a carbon is directly adjacent to a neutral or positively charged nitrogen,
having an electron withdrawing effect. The result is that the carbon is more acidic and
willing to donate its proton to a ready proton acceptor as long as the stereochemistry of
the protein allows for it. It has been estimated that energy of this bond is 2.5 to 3.5
kcal/mol in vaccuo [3]. In recent years several studies have identified

C—H•••O

hydrogen bonds as having an important role in the stabilization of transmembrane
helices[4], β sheets[5] and Schellman motifs[6]. However the role of this weak hydrogen
bond in the activation of proteins is still not fully understood.
C—H•••O hydrogen bonds have also been identified in the active sites of serine
protease.[7] Derewenda et al. surmise that the significance of the C—H•••O hydrogen
bond is to provide an even charge distribution in the imidazole ring of histidine leading to
the deprotonation of the NƐ2 during the cleavage step of acylation and deacylation of the
enzyme[7]. Also that the bonds role is not necessary for stabilization of the imidazole
ring because of the observed preferred trans conformation[7]. However, it has not been
determined if these bond are present in the active sites of cysteine protease. Using
generally accepted distance and angle measurements for C—H•••O hydrogen bonds in
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macromolecules we have determined the presence of C—H•••O hydrogen bond in the
active sites of cysteine proteases.
4.3

Materials and Methods

Using the Merops[1] a dataset of 94 non-homologous structurally characterized
cysteine protease were selected. Each of their coordinate files were downloaded from the
Protein Data bank[8]. A cutoff was for resolution at 3.0 Å and sequence homology of <
80 %. Hydrogen’s were added to the protein database coordinate files using the reduce
program of Molprobity[9]. The stereo chemistry of the C—H•••O bond was analyzed
using the 4 different parameters and seen in Figure 1: C-O bond distance (D); O-H bond
distance (DH); C—H•••O angle (ζ); and H—O=C angle (ξ). Geometric parameters used
in previous C—H•••O studies can be found in Table 1. The parameters as applied to this
study limited the C-O bond distance (D) < 4.0Å, O-H bond distance (DH) <2.8Å, C—
H•••O angle (ζ) > 120 (°)and the H—O=C angle (ξ) was measured but no specific cutoff
was set. The calculation of the bond distances and angles were calculated using
Pymol[10] and recorded into a table 4.4

4.4 Results

4.4.1 C—H•••O Hydrogen Bond In Most Cysteine Protease Active Sites
An analysis of the data reveals the presence of the C—H•••O hydrogen bond in
the active sites of cysteine proteases. We identified 94 structurally characterized cysteine
protease using the Merops[1]. Out of the 94 just 45 (48%) examples were identified as
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having a distance C—H•••O (D) of < 4.0 Å and an H—O (DH) distance of < 2.8 Å with
an average of 3.52Å and 2.50Å respectively. Figure 3A and 3B show the relative
distribution of measured distances in the structures. It reveals that a majority of the C—
H•••O distances are between 3.5Å and 4.0Å. Also the H—O distances vary greatly but
between 2.0Å to 2.8Å.
The CƐ-H--O (ζ) angles were also well within the defined criteria of >1200 with an
average of 1560, while the average H—O=C (ξ) angle was 1270. The distribution of angle
measurements seen in Figure 3B and 3C are very spread out for the CƐ-H--O (ζ) angle
and relatively tight for the H—O=C (ξ) angle. These values are consistent with
previously identified C—H•••O hydrogen bonds as reported in previous C—H•••O
analysis in literature.
The CƐ-H--O hydrogen bond may have its importance in contributing to the
effect on the charge distribution of the catalytic imidazole as suggested by Derewenda et
al[7]. However we also noticed that glutamine was observed to be the most frequent
proton acceptor in the analysis, involved in 32 (34%) of the total 94 proteins studied and
is most noted to be the member of the putative oxyanion hole of cysteine protease.
Previous studies have shown the importance of the oxyanion hole for the stabilization of
the tetrahedral intermediate in the cysteine reaction mechanism and how mutation at this
residue contributes to the reduction in enzyme activity[11]. From its prevalence as the
proton acceptor in the importance of the C-H--O interaction may be to position the
glutamine for immediate stabilization of the tetrahedral intermediate. Figure 4 shows the
presence of the C—H•••O hydrogen bond in UCHL3 (PDB entry 1UCH), a notably very
efficient cysteine protease. The glutamine is held in short contact with the catalytic
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histidine. The CH is approximately 2.0 Å away from the oxygen of the side-chain
carbonyl group. Interestingly, this distance is less than the sum of their van der Walls
radii. This distance, along with C—H•••O and H•••O=C angles of 171° and 122°,
respectively, which meets the geometric criteria used for a C—H•••O hydrogen bond and
therefore qualifies as a significant interaction [3, 4, 12-14]. Inspection of the active sites
of UCHL1 (PDB ID: 3IFW) (bound with ubiquitin vinylmethylester) and UCHL5N240
(PDB ID: 3RIS) also reveals the presence of the same interaction (Table 2), suggesting
that the C—H•••O hydrogen bond involving the active site histidine and glutamine is a
common feature of the UCH enzymes discussed herein [6, 12, 15].

4.4.2

UCHL3 Lysine and Glutamine Mutants Activity not as Expected

In order to better understand the role of the glutamine side chain in the catalytic
reaction, additional mutations converting the glutamine to either a glutamate or a lysine
were carried out (Figure 6). Since results for the glutamine to alanine mutation were
consistent across the three UCH enzymes tested, we limited the experiments to just
UCHL3, which displayed the best geometry for the C—H•••O hydrogen bond among the
UCH enzymes. Mutation of the glutamine to glutamate would allow for a stronger C—
H•••O bond but would eliminate its contribution to oxyanion stabilization. Furthermore,
it would introduce a negative charge that is expected to destabilize the oxyanion species.
Mutation to lysine, on the other hand, would take away the possibility of the C—H•••O
bond while allowing for stronger oxyanion stabilization, assuming that the side-chain
NH3+ group of the lysine would occupy a position similar to the NH2 group of the
glutamine’s side chain. As seen in the previous alanine mutants, replacing the glutamine
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residue with either a glutamate or lysine lowered kcat, while KM remains relatively
unchanged (Table 3). Surprisingly, the Q89E mutation resulted in only a 5-fold reduction
in kcat compared to the wild-type enzyme, an effect that is significantly lower than what
would be expected from the combined effect of both eliminating hydrogen-bonding and
introducing charge-charge repulsion between the glutamate side chain and the oxyanion.
In the case of Q89K, despite our expectation that the mutation would lead to better
oxyanion stabilization, we see a 15-fold loss in kcat, which is roughly the value we see in
the UCHL3 Q89A mutant (compare Table 3.1 with Table 2.1).
In the analysis of 94 structurally characterized cysteine proteases we have seen
evidence of the C—H•••O hydrogen bond in about half of the cysteine protease that we
have analyzed. 45 of the 94 exhibited C—H•••O hydrogen bond from the active site
Histidine (48%)[16]. 32 cases were between the Histidine active site residue and the
Glutamine oxyanion residue (34%). We speculate that this interaction gives a greater
importance for the role of the oxyanion hole residue in cysteine proteases by either
altering the pKa of the general- base His and/or by keeping the oxyanion-stabilizing side
chain in a productive orientation.

An alternative explanation of the difference in

magnitude of Ub-AMC hydrolysis seen between the glutamine to alanine mutants
compared to the wild-type enzymes can be made by invoking the loss of the C—H•••O
contact in the mutant. Inspection of active sites of the UCH enzymes reveal that the
glutamine is in short contact with the catalytic histidine, which satisfies the geometric
constraints for a C—H•••O hydrogen bond. Intrigued by this, we looked at a larger
dataset of QCH(N/D) type of cysteine proteases in the Merops database, which revealed
most cysteine proteases, including papain, possess a conserved glutamine that is within
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C—H•••O bonding distance of the catalytic histidine. It should be noted that in papain,
the glutamine (Gln19) is also known to be involved in an N—H•••O hydrogen bond with
the NH group of the side chain of Trp177 [17], a catalytically important side chain. This
is an example of a carbonyl group simultaneously engaged in hydrogen bonding with a
CH and an NH donor, a situation commonly observed among protein -sheets, in which
the backbone carbonyl groups of one strand are engaged in C—H•••O and N—H•••O
hydrogen bonds with an adjacent strand’s CH and backbone NH groups, respectively
[18]. However this ‘bifurcated’ situation does not exist in UCH enzymes, as there is no
other hydrogen bond donor with accepted distance other than the imidazole group of the
catalytic histidine. The observation of the C—H•••O contact presented here extends the
parallels between serine and cysteine proteases. Dewerenda et al. first observed a C—
H•••O contact involving the catalytic histidine and a backbone carbonyl as the hydrogen
bond donor in the active site of serine proteases [12]. The possibility that such an
interaction plays a role in the catalytic mechanism of cysteine proteases, as has been
suggested for their serine counterparts, cannot be ruled out. Interestingly, the change in
free energy of transition-state stabilization (close to 2 kcal/mol) upon mutation in our
system, as well as in the case of papain, happens to be very much within the range of the
strength of a C—H•••O hydrogen bond [3], [19].
The C—H•••O hydrogen bond can be thought of as an additional force that
stabilizes the imidazole side chain in a productive orientation such that it acts both as a
general base and a proton donor during catalysis. Additionally, the C—H•••O hydrogen
bonding would serve to enhance the histidine’s ability to specifically act as a general base
by transferring some electron density from the glutamine carbonyl to the imidazole ring
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of histidine. A stronger general base would mean a better ability to extract proton from
water to activate it for nucleophilic attack, facilitating the formation of the tetrahedral
transition state during deacylation (Scheme 2.1). Although different cysteine proteases
would employ different mechanisms for hydrolysis, a better general-base histidine will in
general contribute to efficient catalysis. However, the exact mechanism of how the
active-site C—H•••O interaction may play a role in transition-state stabilization needs to
be further investigated by computational work.
We conducted additional studies on UCHL3 to dissect the role of the glutamine
side chain in the deubiquitination reaction. If the sole purpose of glutamine were to
stabilize the oxyanion, removal of the hydrogen-bonding (N-H•••O) donor plus the
placement of a negative charge would substantially destabilize the transition state,
leading to an effect on kcat that would be greater than the alanine mutant. Interestingly,
the glutamine to glutamate mutant (with only a 5-fold decrease in kcat) proved to be a
better catalyst than the alanine mutant, which is inconsistent with the idea that the
glutamine is acting as an oxyanion stabilizer. Instead, the data appears to support that the
C—H•••O hydrogen bond contributes to catalysis. It is likely that the carboxylate side
chain of glutamate in the Q89E mutant makes a stronger C—H•••O interaction with the
CH group of the catalytic histidine than the carboxamide group of glutamine resulting in
a better catalyst than the wild-type protein, but this effect is compensated to some degree
by the unfavorable electrostatics between the negatively charged side chain and the
oxyanion. It should be noted that a previous study showed that Q19E mutation in papain
resulted in an approximately 20-fold decrease in kcat, to a similar level as seen in the
Q19A mutant, leading the authors of that study to propose that he negative charge was
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tolerated in the active site [20]. It is tempting to propose that in papain, the
accommodation of the unfavorable charge in the mutant might have also been due to the
compensatory effect of the C—H•••O hydrogen bond.
We then mutated the glutamine to lysine, which produced an enzyme with
activity comparable to the alanine mutant. This is also surprising because lysine side
chain has two components, NH groups for hydrogen bonding with the oxygen of the
oxyanion, and the charge for favorable electrostatic interaction, and we expected that the
combination of the two, assuming that right geometry is maintained for the N-H•••O
bond, would cause better stabilization of the oxyanion than in the wild-type protein.
However, this mutant showed similar level of catalytic activity as the alanine mutant,
indicating that placement of positive charge near the active site does not appreciably
enhance the stability of the oxyanion species, presumably because the glutamine in the
wild-type enzyme was not playing a role in oxyanion stabilization. Alternatively, the
longer side chain of lysine may be oriented away from the oxyanion with little interaction
between the two, and therefore, the lysine mutant may not be reporting if the glutamine
were stabilizing the oxyanion. On the other hand, since the Q89K mutant lacks the
ability to form the C—H•••O hydrogen bond as the Q89A mutant, the reduction in kcat, to
nearly the same extent as seen in Q89A, might reflect this deficiency.

4.5 Discussion
Earlier we have shown that the active-site glutamine in UCH enzymes contributes
to rate enhancement, but the relatively modest value of transition-state stabilization is
more indicative of a weaker interaction, such as the C—H•••O bond between the
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glutamine and catalytic histidine, than the conventional N-H•••O type of hydrogen bond
that was proposed to stabilize the oxyanion [21]. We now conclude as a result for the
UCHL3 Q89K and Q89E that this active site glutamine gives all the characteristics of a
C—H•••O hydrogen bond. The observation that the glutamate mutant of UCHL3 is more
active than the alanine mutant suggests that the conserved glutamine is unlikely to
contribute to oxyanion stabilization, rather may play a role in catalysis via the C—H•••O
hydrogen bond with the catalytic histidine.
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Figure 4.1: Definition
D
of
o geometricaal parameterrs A. Angulaar parameters. B. Distancce
parameters. Nomenclatu
ure accordin
ng to Dereweenda et al.[1]]
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Table 4.1: Geometric Parameters used in previous studies[6]
D (Å)

DH (Å)

CƐ-H--O (ζ) (°)

H—O=C (ξ) (°)

Reference

<3.5

<2.7

>120

--

[4]

--

<2.7

>90

~120

[12]

--

<2.8

>90

--

[22]

4.0-30

<2.8

>110

120-140

[14]
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Merops Database

Catalytic Type

Obtained structures from
PDB
Generate data set of
highest resolution
structure < 3.0 Å, sequence
homology < 80%
94 non redundant PDB
entries

Family
Hydrogen's added in
Molprobity
Clan

Distance and angles
measured in Pymol

Figure 4.2: Flowchart used to create database. Structurally characterized proteins
identified in the Merops Database[1] which segregates proteins by catalytic type, family’s
by sequence similarity, clan’s by evolutionary relationship. The pdbs were downloaded
from the Protein Data Bank[8]. The C—H•••O distances and angles were then measured
in Pymol[10]
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Table 4.2: C—H•••O hydrogen bond parameters observed in 45 of 94 structurally
characterized cysteine proteases. Hydrogen bond donor and acceptor in bold.
(a)Acceptor is backbone carbonyl oxygen of W280. (b) Acceptor is backbone carbonyl
oxygen of G24 280
Pdb ID

Resolution
(Å)

Active site
residues

D (Å)

DH

CƐ-H--O
(ζ)>120
(0)

H--O-C
(ξ) (0)

9PAP

1.65

C25, H159,
N175,Q19

3.84

2.79

158.6

115.9

1YAL

1.70

C25, H159,
N179 ,Q19

3.72

2.60

172.4

125.2

1PPO

1.80

C25, H159,
N179, Q19

3.69

2.68

153.0

130.4

1MDW

1.95

C105,
H262, N286, 2.97
Q99

1.90

164.0

128.4

1KXR

2.07

S115, Q109,
H272, N296

3.23

2.30

141.7

119.0

1ZIV

2.31

C97, H254,
N278, Q91

3.26a

2.50

128.2

139.6

3IFW

2.4

C90, H161,
D176, Q84

3.71

2.79

141.6

159.1

1UCH

1.80

C95, H169,
D184, Q89

3.11

2.00

171.6

122.1

2GFO

2.00

C786,
H1067,
D1085,
N781

3.31

2.20

172.2

121.0

1VJV

1.74

C118, H447,
3.10
N113, N465

2.10

147.3

102.4
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Table 4.2: continued
D (Å)

DH

CƐ-H--O
(ζ)>120
(0)

H--O-C
(ξ) (0)

C51, H148,
N46, A163

3.27

2.20

156.8

126.2

1.90

C17, H96,
A112, Q11

3.59

2.70

136.2

153.6

1CV8

1.75

C24, H120,
N141, Q18

3.50

2.40

160.4

138.3

2CY7

1.90

C74, D278,
H280, Y54

3.09

2.10

141.9

128.3

3DKB

2.50

C103,
H256, N98

3.96

2.88

167.2

74.7

1Y08

1.93

C94, H262,
D284, D286

3.30

2.28

153.7

88.9

2Z84

1.70

C53, H177,
D175, Y41

3.62

2.75

135.5

161.2

2BU3

1.40

C70, H183,
D201, Q64

3.51

2.41

179.0

150.6

Pdb ID

Resolution
(Å)

Active site
residues

1QMY

1.90

3K8U
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Table 4.2: continued
DH

CƐ-H--O
(ζ)>120
(0)

H--O-C
(ξ) (0)

2.44

128.8

127.2

2.34

128.6

88.9

C580,H514,
3.90
D531,Q574

2.84

160.0

118.0

2.45

C602,H533,
3.82
D550,Q596

2.78

157.5

113.5

2.40

C926,H794,
3.59
D873,Q920

2.59

151.5

137.4

2.20

176.7

136.4

Pdb ID

Resolution
(Å)

Active site
residues

D (Å)

3C0R

2.31

C120,H222,
3.25
D117

3BIJ

2.50

C135, H84

1EUV

1.60

2CKG
3EAY

3.14b

C163,H102,
D119,Q157 3.29

1XT9

2.20

1A2Z

1.73

C143, E80,
H167

3.72

2.82

139.7

100.8

2HWK

2.45

C477, H546 3.70

2.90

129.5

128.8

1GEC

2.10

C25, H159,
Q19

2.06

179.1

150.0

3.61
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Table 4.2: continued
D (Å)

DH

CƐ-H--O
(ζ)>120
(0)

H--O-C
(ξ) (0)

C26, H163,
Q20

3.79

2.69

174.6

138.3

2.67

C31, H180,
N200, Q22

3.88

2.81

163.9

144.6

1CQD

2.10

C27, H161,
N181, Q21

3.98

2.97

152.4

120.8

2FO5

2.20

C28, H167,
N188, Q22

3.66

2.60

162.2

118.0

1CS8

1.80

C25, H163,
Q19

3.68

2.59

168.8

131.4

1GLO

2.20

C25, H164,
Q19

3.33

2.27

161.4

119.7

7PCK

3.20

C25, H162,
Q19

3.48

2.38

173.9

154.1

1YVB

2.70

C25, H159,
Q19

3.83

2.78

159.5

112.1

1HUC

2.10

C29,H199,
Q23, N219

3.55

2.54

153.3

122.5

Pdb ID

Resolution
(Å)

Active site
residues

1S4V

2.00

1EF7
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Table 4.2: continued
D (Å)

DH

CƐ-H--O
(ζ)>120
(0)

H--O-C
(ξ) (0)

C51, H183,
N182, Q45

3.99

2.98

152.8

140.7

1.63

C25, H159,
N178, Q19

3.63

2.54

169.1

137.0

2BDZ

2.10

C25, H159,
N175, Q19

3.57

2.49

168.8

130.2

2PNS

1.90

C25, H157,
N173, Q19

2.88

2.01

132.6

101.0

3F75

1.99

C31, H167,
N189, Q25

3.48

2.38

174.0

139.5

2B1M

2.00

G26, H168,
N175

3.40

2.38

154.7

137.7

1CB5

2.59

C73, H372,
N396, Q67

3.71

2.65

162.1

114.6

1GCB

2.20

C73, H369,
N392, Q67

3.75

2.68

165.9

126.7

Average

3.52

2.50

156.1

127.0

Pdb ID

Resolution
(Å)

Active site
residues

3BWK

2.42

1IWD
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Figure 4.4: C—H•••O bon
nding seen in UCHL3 w
with the cataalytic residuees and the
glutamine sho
own as stick
ks. (A) The D distance. (B
B) The DH ddistance alonng with the ξ and
ζ angles.
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A) Glutamine to glutamaate and (B) lyysine mutannts in UCHL33. The
Figure 4.5: (A
utant showed
d far less deccrease in kcatt , only 5 foldd . The lysinne mutants w
were
glutamate mu
siimilar to the alanine muttant
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Table 4.3: Kinetic Parameters for UCHL3 Glu and Lys mutants showing decrease in
kcat/KM from wild type
UCHL3 Q89E
UCHL3 Q89K

KM (nM)
49.8 ± 11.0
58.5 ± 2.9

kcat (s-1)
3.65 ± 0.00
1.20 ± 0.00

kcat/KM ×104 (M-1 s-1)
7329
1931

ΔΔG≠ (kcal/mol)
0.72
1.51
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Ubiquitin C-terminal hydrolases (UCHs) are cysteine proteases featuring a
classical Cys–His–Asp catalytic triad, and also a highly conserved Gln that
is thought to be a part of the oxyanion hole. However, the contribution of
this side chain to catalysis by UCHs is not known. Herein, we demonstrate
that the Gln side chain contributes to rate enhancement in UCHL1,
UCHL3, and UCHL5. Mutation of the Gln to Ala in these enzymes
impairs the catalytic efﬁciency, mainly because of a 16-fold to 30-fold
reduction in kcat, which is consistent with a loss of approximately
2 kcalÆmol)1 in transition state stabilization. However, the contribution to
transition state stabilization observed here is rather modest for the side
chain’s role in oxyanion stabilization. Interestingly, we discovered that the
carbonyl oxygen of this side chain is engaged in a C–HÆÆÆO hydrogen-bonding contact with the CeH group of the catalytic His. Upon further analysis,
we found that this interaction is a common active site structural feature in
most cysteine proteases, including papain, belonging to families with the
QCH(N ⁄ D) type of active site conﬁguration. It is possible that removal of
the Gln side chain might have abolished the C–HÆÆÆO interaction, which
typically accounts for 2 kcalÆmol)1 of stabilization, leading to the effect on
catalysis observed here. Additional studies performed on UCHL3 by
mutating the Gln to Glu (strong C–HÆÆÆO acceptor but oxyanion destabilizer) and to Lys (strong oxyanion stabilizer but lacking C–HÆÆÆO hydrogenbonding capability) suggest that the C–HÆÆÆO hydrogen bond could contribute to catalysis.

Introduction
Ubiquitin (Ub) C-terminal hydrolases (UCHs) belong
to a larger group of enzymes collectively called
deubiquitinases, which catalyze the hydrolysis of the
peptide or isopeptide bond through which Ub is
attached to other proteins or other Ub moieties in
polyubiquitin chains [1–5]. The UCH family members
are cysteine proteases featuring a classical Cys–His–
Asp catalytic triad [6–10]. The active site of these
enzymes also features a highly conserved Gln (Fig. 1),
which is believed to be a part of the so-called oxyanion
hole, an arrangement of spatially proximal peptide

dipoles aligned in a way that creates a positively
charged pocket facing the thiol group of the catalytic
Cys. It is also possible that, by virtue of being located
at the N-terminus of a helix, the electropositive character of this pocket is enhanced by the helix macrodipole
effect [11]. In cysteine proteases, nucleophilic attack on
the carbonyl group of the scissile peptide bond proceeds through a tetrahedral transition state bearing a
negative charge on the oxygen atom of the carbonyl
group. This negative charge is stabilized by
electrostatic and hydrogen-bonding interactions with

Abbreviations
AMC, aminomethylcoumarin; PDB, Protein Data Bank; Ub, ubiquitin; Ubal, ubiquitin aldehyde; UCH, ubiquitin C-terminal hydrolase.
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Fig. 1. Sequence alignment of the human UCHs and the yeast
homolog Yuh1. Residues corresponding to the catalytic triad are in
red, and the putative oxyanion residue is in blue.

the oxyanion hole, which are proposed to constitute
one of the factors leading to the lowering of activation
energy for the hydrolysis reaction [12].
The relative orientation of the carbonyl oxygen of
the scissile peptide group with respect to the oxyanionstabilizing groups, as in the tetrahedral transition state,
may be approximately visualized in the crystal structure of the yeast Ub hydrolase Yuh1 bound covalently
to the suicide substrate Ub aldehyde (Ubal) (Fig. 2)
[13]. Attack of the catalytic thiol on Ubal results in the
formation of the thiohemiacteal product, which mimics
the oxyanion-bearing tetrahedral transition state
(Fig. 2). As seen in Fig. 2, the hydroxyl oxygen of the
thiohemiacetal moiety is within a relatively short distance from the backbone NH groups of the catalytic
Cys90, Ala89 and Asn88 and the side chain NH2
group of Gln84, the putative oxyanion-stabilizing side
chain. It has been proposed that, in a general cysteine

Role of active site glutamine in UCH catalysis

protease, the negatively charged oxygen in the tetrahedral transition state would occupy nearly the same
position as the thiohemiacteal hydroxyl oxygen seen in
the Yuh1–Ubal structure and would be coordinated
through electrostatic and hydrogen-bonding interactions with the groups lining the oxyanion hole [13].
Previous studies in papain revealed that Gln19, the
oxyanion side chain in the protein, plays a role in the
catalytic mechanism of the enzyme contributing to rate
enhancement. Mutation of this side chain to Ala
reduces the catalytic efﬁciency by approximately
60-fold, mostly affecting kcat (20-fold lower), with a
smaller change in Km (three-fold higher) [12]. Ignoring
the relatively small change in Km, the 20-fold change
in kcat was attributed to a loss of the contribution of
the Gln side chain to oxyanion stabilization. The catalytic Cys–His–Asp triad of structurally characterized
UCHs, such as UCHL1, UCHL3, and UCHL5, adopts
a similar geometric relationship as found in the Cys–
His–Asn triad of papain and the triads of other
papain-like cysteine proteases. Additionally, the active
site Gln in UCH enzymes is located in an analogous
position to Gln19 in the active site of papain. However, the role played by this side chain in catalysis by
UCHs has not been studied thus far. Considering the
importance of the UCH group of proteases in diseases
such as Parkinson’s disease and cancer, dissecting the
role of active site residues in catalysis by these enzymes
is an important endeavor, as it would advance our
understanding of the mechanism of these enzymes
[14–18]. In this study, we sought to determine the contribution to rate enhancement by the putative oxyanion-stabilizing side chain of the active site Gln by
mutational analysis and comparison of the kinetic
parameters with those of the wild-type proteins. This
was investigated in all structurally characterized
UCHs – UCHL1, UCHL3, and the catalytic domain
of UCHL5 (residues 1–240, hereafter referred to as
UCHL5N240) [6–10]. Breast cancer early-onset 1-associated protein 1, the remaining human UCH family
member, was omitted from this study, as its crystal
structure has yet to be determined.

Results
Active site Gln ﬁ Ala mutants of UCHs show
signiﬁcantly less activity than the wild-type
enzymes
Fig. 2. Ubal (gray) covalently bound to Yuh1 (green). Hydrogen
bonding distances are shown for Yuh1 residues stabilizing the thiohemiacetal hydroxyl oxygen on the aldehyde moiety. The helix of
Yuh1 that may contribute to the macrodipole is in magenta.

In order to determine whether the conserved Gln
found in the active site of UCHs (Fig. 1) contributes
to rate enhancement, hydrolysis assays with the ﬂuorogenic substrate Ub-aminomethylcoumarin (AMC) were
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conducted, with identical conditions for each enzyme
and its Gln ﬁ Ala mutant. These results showed that
the rate of hydrolysis leading to AMC release was signiﬁcantly reduced for the mutants as compared with
their wild-type counterparts (Fig. S1), suggesting a role
for this side chain in contributing to rate enhancement
in the catalytic mechanism of the enzymes. As Gln is
located in the solvent-accessible active site of the
enzymes, the mutation of this residue to Ala is not
expected to cause any signiﬁcant perturbation in the
active site structure or gross changes in the threedimensional fold of the protein. In fact, the CD spectra of the mutants produced patterns that were nearly
identical in shape and intensity to those of their corresponding wild-type proteins (Fig. S2), conﬁrming that
the mutation has no observable structural effect in
these proteins.
The reduction in catalytic activity observed upon
mutation could be attributable to two possible factors:
an increase in Km, or a reduction in kcat, the rate constant of the rate-determining step in the hydrolysis
reaction. In order to determine which parameters are
affected by the mutation, we set out to analyze the
Michaelis–Menten kinetics of the mutants and the
wild-type enzymes. Additional activity assays were
conducted with varying substrate concentrations, and
plots of the initial velocities versus substrate concentration are shown in Fig. 3. All enzymes, with the exception of UCHL5N240 Q82A, were ﬁtted to the
Michaelis–Menten equation (Fig. 3F). Nonlinear
regression analysis of the plots yielded the kinetic
parameters kcat and Km for each UCH variant, and
their values are provided in Table 1. The values of the
kinetic parameters obtained with wild-type enzymes
were consistent with previously reported values [19–
21]. For UCHL1 and UCHL3, the Gln ﬁ Ala mutants
showed 30-fold and 18-fold decreases in kcat, respectively, as compared with their corresponding wild-type
enzymes. However, Km values were relatively
unchanged by the mutation, which is consistent with
the hypothesis that the Gln is involved in the catalytic
mechanism of the enzyme.
In the case of UCHL5N240 Q82A, kcat and Km
could not be determined individually, because, even at
concentrations of Ub-AMC as high as 12 lm, the
Michaelis–Menten plot was still rising linearly with
substrate concentration, not reaching the plateau that
is diagnostic of saturation. Substrate concentrations
> 12 lm result in dimethylsulfoxide concentrations
higher than 5%, which can diminish the enzyme’s
activity. Instead, the kcat ⁄ Km ratio was determined by
dividing the slope of this linear plot by the total
enzyme concentration, as it can be assumed that, in
1108

this region of the Michaelis–Menten plot, [UbAMC] > Km. Comparison of this value for the wildtype and Q82A variant of UCHL5N240 showed a
16-fold reduction in catalytic efﬁciency, which was
comparable to the reductions seen with UCHL1 and
UCHL3, suggesting that Gln82 is probably performing
the same function as in the other UCH enzymes.
In order to determine the effect of these mutations
on the stabilization of the transition state, we sought
to estimate the change in free energy of activation
associated with the mutation. The calculation was carried out with Eqn (1) and the kcat ⁄ Km values mentioned above and reported in Table 1 [12]. The free
energy change for the three enzymes was approximately 2 kcalÆmol)1, which is consistent with the value
reported for the same mutation in papain [12].
"

ðkcat =Km Þmutant
DDG ¼ RT ln
ðkcat =Km Þwild-type
6¼

#
ð1Þ

The active site Gln in UCHs is involved in a
C–HÆÆÆO hydrogen bond with CeH of the catalytic His
The loss in enzymatic activity seen in the Gln ﬁ Ala
mutants prompted us to look closely at the interactions of the active site Gln with nearby residues.
Figure 4 shows the active site neighbors of Gln in
UCHL3 [Protein Data Bank (PDB) entry 1UCH].
Interestingly, the Gln is in close proximity to the catalytic His, with the CeH being 2.0 Å away from the
oxygen of the side chain carbonyl group, a distance
less than the sum of their van der Waals radii. This
distance, along with C–HÆÆÆO and HÆÆÆO=C angles of
171 and 122, respectively, meets the geometric criteria used for a C–HÆÆÆO hydrogen bond, and this interaction therefore qualiﬁes as a signiﬁcant interaction
[22–26]. Inspection of the active sites of UCHL1 (PDB
ID: 3IFW) (bound with Ub vinylmethylester) and
UCHL5N240 (PDB ID: 3RIS) also reveals the presence of the same interaction (Table 2), suggesting that
the C–HÆÆÆO hydrogen bond involving the active site
His and Gln is a common feature of the UCHs discussed herein [22,27,28].
This observation led us to wonder whether such a
hydrogen bond also exists in papain and other papainlike cysteine proteases. To this end, we created a dataset of structurally characterized cysteine proteases
found in the MEROPS database that contain, in addition to the three members of the catalytic triad
CH(N ⁄ D), the conserved Gln in their active site (see
Experimental procedures) [29]. The list of all proteins
in the dataset and relevant information about them is
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A

B

C

D

E

F

Fig. 3. Deubiquitination activity assay for determination of catalytic parameters. Data were ﬁtted to the Michaelis–Menten equation to determine the kcat and Km parameters for each enzyme and the corresponding Gln ﬁ Ala mutants. Wild-type UCHL1 (A) and UCHL1 Q84A (B)
are shown as squares, wild-type UCHL3 (C) and UCHL3 Q89A (D) are shown as diamonds, and wild-type UCHL5N240 (E) and UCHL5N240
Q82A (F) are shown as circles.

presented in Table 2. The His–Gln (Ce–Od) distance
and angle distributions within the members of the
dataset are shown as a histogram in Fig. 5. Of 46
structures, 80% (37) satisﬁed the criteria for a C–HÆÆÆO
interaction. The remaining nine proteins met the

angular requirements for the C–HÆÆÆO bond, but did
not meet the distance requirements. However, it should
be noted that, in general, a hydrogen bond has a signiﬁcant electrostatic component, which will be functional even at relatively longer distances, albeit with a
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Table 1. Kinetic parameters for UCHs.

Enzyme

Km (nM)

kcat (s–1)

kcat ⁄ Km · 104
(M–1Æs–1)

DDG
(kcalÆmol)1)

UCHL3
UCHL3 Q89A
UCHL1
UCHL1 Q84A
UCHL5N240
UCHL5N240 Q82A

77.1 ± 8.2
99.1 ± 13.5
47.0 ± 6.0
56.1 ± 2.3
21 493.2
–

18.60 ± 0.60
1.03 ± 0.05
(0.0348 ± 1.25) · 10)3
(0.0011 ± 1.50) · 10)4
33.67
–

24 140
1040
74.1
1.96
15.7
0.966

1.89
2.19
1.68

Fig. 4. Ribbon diagram of UCHL3 with the catalytic residues and the C–HÆÆÆO bonding Gln shown as sticks. (A) The D-value. (B) The DH-value
along with the n and f angles.

weaker effect [24]. Among the 37 structures that met
the criteria, there were ﬁve instances in the dataset
where inactive forms of the protein did not meet C–
HÆÆÆO speciﬁcations; however the bond criteria were
satisﬁed once the protein was in an active conformation upon complexation with either an inhibitor or a
substrate mimic (Table 2). Table 2 shows that a majority of the C–HÆÆÆO distances were between 3.1 and
4.5 Å, with a mean value of 3.7 Å. Additionally, the
HÆÆÆO distances varied between 2.1 and 3.3 Å with a
mean value of 2.6 Å. The Ce–HÆÆÆO (f) angles were
also well within the deﬁned criteria of > 120, with a
mean of 161, whereas the mean HÆÆÆO=C (n) angle
was 134.
In order to better understand the role of the Gln
side chain in the catalytic reaction, additional mutations converting the Gln to either a Glu or a Lys were
carried out (Fig. 6). As the results for the Gln ﬁ Ala
mutation were consistent across the three UCHs
tested, we limited the experiments to just UCHL3,
which displayed the best geometry for the C–HÆÆÆO
1110

hydrogen bond among the UCHs. Mutation of the
Gln to Glu would allow for a stronger C–HÆÆÆO bond,
but would eliminate its contribution to oxyanion stabilization. Furthermore, it would introduce a negative
charge that is expected to destabilize the oxyanion species. Mutation to Lys, on the other hand, would take
away the possibility of the C–HÆÆÆO bond while allowing for stronger oxyanion stabilization, on the assumption that the side chain NH3+ group of the Lys would
occupy a position similar to the NH2 group of the Gln
side chain. As seen in the previous Ala mutants,
replacing the Gln with either a Glu or a Lys lowered
kcat, whereas Km remained relatively unchanged
(Table 3). Surprisingly, the Q89E mutation resulted in
only a ﬁve-fold reduction in kcat as compared with the
wild-type enzyme, an effect that is signiﬁcantly lower
than what would be expected from the combined effect
of both eliminating hydrogen bonding and introducing
charge–charge repulsion between the Glu side chain
and the oxyanion. In the case of the Q89K mutant,
despite our expectation that the mutation would lead
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Table 2. C–HÆÆÆO hydrogen bond parameters observed in 46 structurally characterized cysteine proteases with QCH(N ⁄ D)-type active site
conﬁgurations from the MEROPS database.

Clan

Family

PDB

Protein

Resolution

Active site
residues

CA

C1

1PE6
1YAL
1PPO
1GEC

Papain
Chymopapain
Caricain
Glycyl endopeptidase
(Carica papaya)
Actinidain
Cathepsin V
Vignain
Cathepsin X
Zingipain
Cathepsin F
Endopeptidase B
(barley-type)
Cathepsin L
Cathepsin S
Cathepsin K
Cathepsin H
Falcipain-2
Cathepsin B
Falcipain-3
Dipeptidyl-peptidase I
Rhodesain
Peptidase 1 (mite)
Cruzipain
Ervatamin B
Ervatamin C
Mexicain
Ervatamin A
TgCPL peptidase
(Toxoplasma gondii)
Papain-like protein
SPE31 (Pachyrhizus erosus)
Bleomycin hydrolase (animal)
Calpain-1
Calpain-2
Ubiquitinyl hydrolase L1
Ubiquitinyl hydrolase L3
Ubiquitinyl hydrolase YUH1
Ubiquitin C-terminal hydrolase L5
Bacteriocin-processing peptidase
Staphopain A
Staphopain B
c-Glutamylcysteine
dipeptidyltranspeptidase
Adenain
SENP7 peptidase
SENP8 peptidase
Ulp1 peptidase
SENP1 peptidase
SENP2 peptidase

2.1
1.7
1.8
2.1

Q19,
Q19,
Q19,
Q19,

C25,
C25,
C25,
C25,

H159,
H159,
H159,
H159,

1.7
1.6
2.0
2.7
2.1
1.7
2.2

Q19,
Q19,
Q20,
Q22,
Q21,
Q19,
Q22,

C25,
C25,
C26,
C31,
C27,
C25,
C28,

H162,
H163,
H163,
H180,
H161,
H159,
H167,

1.8
2.2
3.2
2.4
2.7
2.1
2.5
2.2
1.2
1.6
1.6
1.6
1.9
2.1
2.8
2.0

2ACT
1FH0a
1S4V
1EF7b
1CQDa
1M6D
2FO5
1CS8
1GLO
7PCK
1NB5b,c
1YVB
1HUCc
3BPM
1K3Bc
2P86a
1XKG
1F2Aa
1IWD
1O0Ea
2BDZ
3BCNc
3F75
2B1M

C2
C12

C39
C47
CE

C83
C5
C48

a

1CB5
1KXR
1MDW
3IFWb
1UCH
1CMXc
3IHR
3K8U
1CV8
1X9Ya
2BU3c
1AVPa
3EAY
1XT9
1EUVb
2CKG
1TH0a

Does not meet our criteria for CHO hydrogen bond.
ping of Gln or His.

b

D (Å)

DH (Å)

f ()

n ()

N175
N179
N179
N179

3.7
3.7
3.7
3.6

2.6
2.6
2.7
2.1

167.4
172.4
153.0
179.1

135.6
125.2
130.4
150.0

N182
N187
N183
N200
N181
N175
N188

3.5
4.2
3.8
3.9
4.0
3.8
3.7

2.5
3.2
2.7
2.8
3.0
2.8
2.6

162.0
162.7
174.6
163.9
152.4
146.7
162.2

124.0
137.9
138.3
144.6
120.8
155.6
118.0

Q19, C25, H163, N187
Q19, C25, H164, N184
Q19, C25, H162, N182
Q19, C25, H159, N158
Q19, C25, H159, N175
Q23, C29, H199, N219
Q45, C51, H183, N182
Q228, C234, H381, N403
Q19, C25, H162, N182
Q108, C114, H250, N270
Q19, C25, H159, N175
Q19, C25, H159, N178
Q19, C25, H157, N173
Q19, C25, H159, N175
Q19, C25, H157, N173
Q25, C31, H167, N189

3.7
3.3
3.5
3.4
3.8
3.6
3.9
3.4
4.3
3.4
4.1
3.6
4.0
3.6
3.1
3.5

2.6
2.3
2.4
2.4
2.8
2.5
2.8
2.3
3.3
2.3
3.0
2.5
3.0
2.5
2.1
2.4

168.8
161.4
173.9
152.3
159.5
153.3
165.0
172.4
152.8
165.0
164.0
169.1
168.1
168.8
154.7
174.0

131.4
119.7
154.1
162.4
112.1
122.5
98.9
131.2
141.3
135.6
137.7
137.0
131.3
130.2
150.9
139.5

2.0

Q20, G25, H168, N188

3.4

2.4

154.7

137.7

2.6
2.1
2.0
2.4
1.8
2.3
3.0
1.9
1.8
2.5
1.4

Q67, C73, H372, N396
Q109, C115, H272, N296
Q99, C105, H262, N286
Q84, C90, H161, D176
Q89, C95, H169, D184
Q84, C90, H166, D181
Q82, C88, H164, D179
Q11, C17, H96, D112
Q18, C24, H120, N141
Q237, C243, H340, N360
Q64, C70, H183, D201

3.7
3.2
3.0
3.7
3.1
4.1
3.6
3.6
3.5
4.0
3.5

2.7
2.3
1.9
2.8
2.0
3.1
2.8
2.7
2.4
2.9
2.4

162.1
141.7
164.0
141.6
171.6
159.4
133.6
136.2
160.4
164.6
179.0

114.6
119.0
128.4
159.2
122.1
140.8
160.1
153.6
138.3
123.4
150.6

2.6
2.4
2.2
1.6
2.5
2.2

Q115,
Q920,
Q157,
Q574,
Q596,
Q542,
AVG

4.5
3.6
3.3
3.9
3.8
3.9
3.7

3.5
2.6
2.2
2.8
2.8
2.9
2.6

156.5
151.5
176.7
160.0
157.5
154.4
161.1

100.5
137.4
136.4
145.6
118.0
122.3
133.7

C122,
C926,
C163,
C580,
C602,
C549,

H54, E71
H794, D873
H102, D119
H514, D531
H533, D550
H478, D495

Satisﬁes our criteria upon complex formation.
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Fig. 5. (A) Distribution of distances (D) between the active site His Ce–HÆÆÆO contact of the side chain or backbone carbonyl. (B) Distribution
of distances (DH) HÆÆÆO–C. (C) Distribution of angles between Ce–HÆÆÆO (f). (D) Distribution of angles between the HÆÆÆO–C (n) contact of the
side chain or backbone carbonyl.

to better oxyanion stabilization, we saw a 15-fold
reduction in kcat, which is approximately the value that
we saw in the UCHL3 Q89A mutant (compare Table 1
with Table 3).

Discussion
The UCH subfamily of deubiquitinases are cysteine
proteases with a catalytic triad similar to that seen in
the papain family. In each member of this family, as in
papain, there is a conserved Gln located in the active
site of the enzymes that is believed to stabilize the
incipient negative charge on the carbonyl of the scissile
bond during the transition state of the hydrolysis reaction (Scheme 1). Indeed, mutation of the Gln19 in
papain to Ala resulted in a 60-fold decrease in catalytic
efﬁciency, owing mainly to a diminished catalytic
rate (20-fold) and a small loss in substrate binding
(three-fold). These results support the claim that the
1112

conserved Gln side chain contributes to the stabilization of the oxyanion transition state. Given the similarity in certain active site residues between papain and
members of the UCH family, we wondered whether
the Gln would perform a similar role in the UCH family. The study presented herein sought to address the
role of the conserved Gln in rate enhancement in three
UCHs.
Through site-directed mutagenesis, the active site
Gln in three structurally characterized members of the
UCH family was replaced with Ala, in order to assess
the contribution of this side chain to rate enhancement. Deubiquitination assays show there is a signiﬁcant loss of activity in mutant enzymes as compared
with their wild-type counterparts. Comparison of the
kinetic parameters shows a 16-fold to 30-fold reduction
( 2 kcalÆmol)1) in the catalytic efﬁciency for the Gln
mutants, which is attributable mainly to a decrease in
the kcat parameter, as seen in UCHL1 and UCHL3
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Fig. 6. Activity assay for UCHL3 mutants ﬁtted to the Michelis–
Menten equation for determination of Km and kcat. (A) UCHL3
Q89E is shown as open circles. (B) UCHL3 Q89K is shown as ﬁlled
triangles.

(for the mutant UCHL5, kcat and Km could not be separately determined). These results are in agreement
with the aforementioned results for papain, although
the UCHs did not exhibit the same change in Km
value. The kinetic scheme for UCHL1 has been
worked out by Case and Stein, using the same UbAMC substrate [20]. Their study showed that the rate
of acylation is rate-limiting for kcat, which means that
Km is reduced to the dissociation constant (Kd) of the
Michaelis complex. The fact that we do not see any
signiﬁcant change in Km suggests that Gln84 in

Table 3. Kinetic parameters for UCHL3 mutants.

Km (nM)

kcat (s)1)

kcat ⁄ Km · 104 DDG „
(M)1Æs)1)
(kcalÆmol)1)

UCHL3 Q89E 49.8 ± 11.0 3.65 ± 0.00 7329
UCHL3 Q89K 58.5 ± 2.9 1.20 ± 0.00 1931

0.72
1.51

UCHL1 does not contribute to the enzyme–ground
state–substrate complex. Therefore, in UCHL1,
according to our studies, the active site Gln does not
make any appreciable contact with the substrate in the
Michaelis complex; rather, it helps to stabilize the transition state.
The kinetic scheme for UCHL3 remains to be
worked out. However, kcat values of UCHL3-catalyzed
hydrolysis of Ub ethylester and Ub-lysine are very similar to that obtained with Ub-AMC as the substrate,
suggesting that deacylation might be the rate-limiting
step [19]. In such a case, Km is not the simple dissociation constant of the Michaelis complex. Nevertheless,
the fact that Km changes only slightly upon Gln ﬁ Ala
mutation in UCHL3 is consistent with the inference
that the Gln does not appreciably contribute to the
Michaelis complex.
As discussed before, we could not separately measure kcat and Km for UCHL5N240 Q82A; rather, the
ratio was measured, which is about 16-fold less than
that for the wild-type protein. It is possible that the
ratio reﬂects a change mostly in kcat, as for UCHL1
and UCHL3, because of the structural similarity
between the proteins. However, it cannot be ruled out
that UCHL5N240 employs a different mechanism
from UCHL1 and UCHL3. It is possible that there
was a much larger change in kcat that was compensated for by an opposite change in Km. Alternatively,
there was little or no change in kcat and the observed
effect was attributable mostly to a change in Km. The
latter possibility seems rather unreasonable, as the Gln
is located in an almost identical position as in the
other enzymes, and its effect on stabilizing the Michaelis–Menten complex is therefore expected to be the
same.
Our results indicate that the mutation of Gln to Ala
results in a signiﬁcant reduction in the catalytic rate,
supporting the hypothesis that Gln functions to stabilize the transition state intermediate(s). However, one
would expect the change to be much > 30-fold, as
seen in our system, if the mechanism acted through the
stabilization of the oxyanion, which has been proposed
to involve hydrogen bonding between the NH2 group
of the side chain of Gln and the negatively charged
oxygen ion, given that such hydrogen bonds are
particularly strong. For example, mutation of the
oxyanion-stabilizing residue Tyr16 to Phe in ketosteroid isomerase results in a 20 000-fold (6.3 kcalÆmol)1)
reduction in kcat [30]. One explanation for the discrepancy between the result of the mutation of the oxyanion-stabilizing side chain in ketosteroid isomerase and
our system is that, in the latter, the side chain of Gln
is not solely responsible for stabilizing the oxyanion
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Scheme 1. Mechanism for the hydrolysis of ubiquitinated constructs by UCHs. Active site residues of the enzyme are in black, and the
ubiquitinated substrate is in gray. The oxyanion interaction is indicated with dashed lines.

through hydrogen bonding; rather, it plays a role in
contributing to the overall electropositive character of
the oxyanion hole. As shown in Fig. 2, a number of
aNH dipoles from surrounding backbone residues can
still support a signiﬁcant degree of oxyanion stabilization even in the absence of the Gln side chain. As
main chain atoms cannot be removed by traditional
mutagenesis methods, the individual contribution of
each atom cannot be determined, and nor can we
determine whether the Gln plays a more signiﬁcant
role than the individual backbone atoms. The alternative possibility, that the transition state stabilization by
the Gln side chain reﬂects a somewhat weaker hydrogen bond, owing to a longer distance between the
donor and the acceptor (Fig. 2), cannot be ruled out.
An alternative explanation for the difference in magnitude of Ub-AMC hydrolysis seen between the
1114

Gln ﬁ Ala mutants and the wild-type enzymes
involves the loss of the C–HÆÆÆO contact in the mutant.
Inspection of active sites of the UCHs reveals that the
Gln is in close proximity to the catalytic His, which
satisﬁes the geometric constraints for a C–HÆÆÆO hydrogen bond. Intrigued by this, we looked at a larger
dataset of QCH(N ⁄ D)-type cysteine proteases in the
MEROPS database, and this revealed that most cysteine proteases, including papain, possess a conserved
Gln that is within C–HÆÆÆO bonding distance of the catalytic His. It should be noted that, in papain, Gln19 is
also known to be involved in an N–HÆÆÆO hydrogen
bond with the NH group of the side chain of Trp177
[31], a catalytically important side chain. This is an
example of a carbonyl group being simultaneously
engaged in hydrogen bonding with a CH and an NH
donor, a situation that is commonly observed among
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protein b-sheets, in which the backbone carbonyl
groups of one strand are engaged in C–HÆÆÆO and
N–HÆÆÆO hydrogen bonds with an adjacent strand’s
CaH and backbone NH groups, respectively [32].
However this ‘bifurcated’ situation does not exist in
UCHs, as there is no other hydrogen bond donor with
an acceptable distance other than the imidazole group
of the catalytic His. The observation of the C–HÆÆÆO
contact presented here extends the parallels between
serine and cysteine proteases. Dewerenda et al. ﬁrst
observed a C–HÆÆÆO contact involving the catalytic His
and a backbone carbonyl as the hydrogen bond donor
in the active site of serine proteases [22]. The possibility that such an interaction plays a role in the catalytic
mechanism of cysteine proteases, as has been suggested
for their serine counterparts, cannot be ruled out.
Interestingly, the change in free energy of transition
state stabilization (close to 2 kcalÆmol)1) upon mutation in our system, as well as in the case of papain,
happens to be very much within the range of the
strength of a C–HÆÆÆO hydrogen bond [26].
The C–HÆÆÆO hydrogen bond can be thought of as
an additional force that stabilizes the imidazole side
chain in a productive orientation such that it acts both
as a general base and as a proton donor during catalysis. Additionally, the C–HÆÆÆO hydrogen bonding
would serve to enhance the His residue’s ability to speciﬁcally act as a general base by transferring some
electron density from the Gln carbonyl to the imidazole ring of His. A stronger general base would mean
a better ability to extract a proton from water to activate it for nucleophilic attack, facilitating the formation of the tetrahedral transition state during
deacylation (Scheme 1). Although different cysteine
proteases would employ different mechanisms for
hydrolysis, a better general base His will, in general,
contribute to efﬁcient catalysis. However, the exact
mechanism by which the active site C–HÆÆÆO interaction may play a role in transition state stabilization
needs to be further investigated by computational
work.
We conducted additional studies on UCHL3 to dissect the role of the Gln side chain in the deubiquitination reaction. If the sole purpose of Gln were to
stabilize the oxyanion, removal of the hydrogen-bonding (N–HÆÆÆO) donor plus the placement of a negative
charge would substantially destabilize the transition
state, leading to an effect on kcat that would be greater
than that in the Ala mutant. Interestingly, the
Gln ﬁ Glu mutant (with only a ﬁve-fold decrease in
kcat) proved to be a better catalyst than the Ala
mutant, which is inconsistent with the idea that the
Gln is acting as an oxyanion stabilizer. Instead, the
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data appear to support the idea that the C–HÆÆÆO
hydrogen bond contributes to catalysis. It is likely that
the carboxylate side chain of Glu in the Q89E mutant
undergoes a stronger C–HÆÆÆO interaction with the CeH
group of the catalytic His than the carboxamide group
of Gln, resulting in a better catalyst than the wild-type
protein, but this effect is compensated for to some
degree by the unfavorable electrostatics between the
negatively charged side chain and the oxyanion. It
should be noted that a previous study showed
that Q19E mutation in papain resulted in an approximately 20-fold decrease in kcat, to a similar level as
seen in the Q19A mutant, leading the authors of that
study to propose that the negative charge was tolerated in the active site [33]. It is tempting to propose
that, in papain, the accommodation of the unfavorable
charge in the mutant might have also been attributable
to the compensatory effect of the C–HÆÆÆO hydrogen
bond.
We then mutated the Gln to Lys, which produced
an enzyme with activity comparable to that of the Ala
mutant. This is also surprising, because the Lys side
chain has two components, NH groups for hydrogen
bonding with the oxygen of the oxyanion, and the
charge for favorable electrostatic interaction, and we
expected that the combination of the two, assuming
that right geometry is maintained for the N–HÆÆÆO
bond, would cause better stabilization of the oxyanion
than in the wild-type protein. However, this mutant
showed a similar level of catalytic activity as the Ala
mutant, indicating that placement of a positive charge
near the active site does not appreciably enhance the
stability of the oxyanion species, presumably because
the Gln in the wild-type enzyme was not playing a
role in oxyanion stabilization. Alternatively, the longer
side chain of Lys may be oriented away from the oxyanion with little interaction between the two. On the
other hand, as the Q89K mutant lacks the ability to
form the C–HÆÆÆO hydrogen bond, the reduction in kcat
to nearly the same extent as seen in the Q89A mutant
might reﬂect this deﬁciency.
In conclusion, we have shown that the active site
Gln in UCHs contributes to rate enhancement, but the
relatively modest value of transition state stabilization
is more indicative of a weaker interaction, such as the
C–HÆÆÆO bond between the Gln and catalytic His, than
the conventional N–HÆÆÆO type of hydrogen bond that
was proposed to stabilize the oxyanion. The observation that the Glu mutant of UCHL3 is more active
than the Ala mutant suggests that the conserved Gln is
unlikely to contribute to oxyanion stabilization, and
rather may play a role in catalysis via the C–HÆÆÆO
hydrogen bond with the catalytic His.
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Experimental procedures
General
The Ub-AMC used for hydrolysis assays was purchased
from Boston Biochem (Boston, MA, USA). The glutathione
afﬁnity column (GSTPrep FF 16 ⁄ 10), gel ﬁltration column
(HiLoad 16 ⁄ 60 Superdex 75) and PreScission protease were
purchased from GE Biosciences (Piscataway, NJ, USA). All
ﬂuorescence assays were performed on a TECAN Genios
microplate spectroﬂuorometer. Buffer and salt components
were purchased from either Sigma-Aldrich (St Louis, MO,
USA) or RPI Corp. (Mount Prospect, IL, USA).

Mutagenesis, expression and puriﬁcation of
proteins
The genes for UCHL1, UHCL3 and UCHL5N240 were
cloned into the pGEX-6P-1 vector with standard protocols,
and subsequently used to mutate the active site Gln to Ala
through PCR reactions with the Quickchange II (Agilent,
Santa Clara, CA, USA) site-directed mutagenesis kit. All
plasmids were transformed into Rosetta2 Escherichia coli
cells and grown to a A600 nm of 0.6 in LB medium supplemented with 100 lgÆmL)1 ampicillin, and then induced with
0.5 mm isopropyl thio-b-d-thiogalactoside and grown overnight at 18 C. Cells were harvested at 6000 g and resuspended in 1· NaCl ⁄ Pi + 400 mm KCl (buffer A). Cells
were passed through a French press twice at 1200 p.s.i.,
and the lysate was cleared by centrifugation at 30 000 g for
1 h. The supernatant was loaded onto a glutathione afﬁnity
column, washed with three column volumes of buffer A,
and eluted with 250 mm Tris, 500 mm KCl, and 10 mm
reduced l-glutathione (pH 8.0). The eluted sample was dialyzed against 1· NaCl ⁄ Pi, 400 mm KCl, and 1 mm dithiothreitol, to which Precission Protease was added to
remove the glutathione S-transferase tag, which was captured on a glutathione–agarose afﬁnity column. The resulting glutathione S-transferase-cleaved protein solution was
passed through a Superdex S75 gel ﬁltration column with
50 mm Tris ⁄ HCl (pH 7.6), 150 mm NaCl, and 1 mm dithiothreitol. Fractions containing puriﬁed protein were
pooled, concentrated, and then ﬂash-frozen in liquid nitrogen and stored at )80 C until use.

C–HÆÆÆO analysis
From the MEROPS database, a dataset of 46 nonhomologous structurally characterized cysteine proteases were
selected belonging to families with a QCH(N ⁄ D) type of
active site conﬁguration [29]. Structures with a resolution
lower than 3 Å were excluded from the dataset. Each of the
coordinate ﬁles was downloaded from the PDB, and hydrogens were added to the protein structures with the reduce
program under molprobity [34,35]. The stereochemistry of
the C–HÆÆÆO bond was analyzed with the four different criteria for parameters shown in Fig. 7: C–O bond distance
(D); HÆÆÆO bond distance (DH); C–HÆÆÆO angle (f); and
HÆÆÆO=C angle (n). The geometric parameters used in the
present and previous C–HÆÆÆO studies can be found in
Table 4. The bond distances and angles were calculated
with pymol (DeLano Scientiﬁc) and are shown in Table 2.

Fig. 7. Deﬁnition of geometric parameters. (A) Angular parameters.
(B) Distance parameters.

Table 4. Geometric parameters for C–HÆÆÆO hydrogen bonding

Kinetic assay to measure Km and kcat values
Each of the UCHs was diluted in assay reaction buffer
(50 mm Tris, pH 7.6, 0.5 mm EDTA, 0.1% BSA, 5 mm
dithiothreitol), so that the ﬁnal concentrations in the reaction were as follows: UCHL1, 2 nm; UCHL1 Q84A, 8 nm;
UCHL3, 5 pm; UCHL3 Q89A, 175 pm; UCHL5N240,
500 pm; UCHL5N240 Q82A, 3 nm; UCHL3 Q89E, 12 pm;
and UCHL3 Q89K, 50 pm. Enzyme was added to a 96-well

1116

plate, and incubated at 30 C for 5 min prior to addition of
Ub-AMC diluted in assay reaction buffer to initiate the
reaction. Rates of Ub-AMC cleavage were monitored with
an excitation wavelength of 380 nm and an emission wavelength of 465 nm at 30 C. Initial reaction rates were calculated and plotted against Ub-AMC concentrations in
sigmaplot, and ﬁtted to the Michaelis–Menten equation to
determine Km and kcat values.

D (Å)

DH (Å)

f ()

n ()
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> 120
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>
>
>
>

–
 120
–
120–140

Present
study
[23]
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